Vertex bought the San Diego startup, projecting over $5 million in revenue per year for Crinetics developments.

The FDA has approved Lipfendra, the first oral PCSK9 inhibitor, for the treatment of high cholesterol. Two medical experts explain why this matters.

A significant breakthrough in heart disease prevention arrived on July 16, 2026, with the FDA approval of Lipfendra ...

The FDA says it can't license Regenative Lab's overseas sales today because it might change its regulations tomorrow. Now, ...

Credit: Merck. Supported by the phase 3 CORALreef program, Merck’s once-daily oral macrocyclic peptide offers a non-injectable PCSK9-targeting pathway to significantly clear LDL-C in adults. Lipfendra ...

Merck’s Lipfendra, the brand name for cholesterol-lowering enlicitide, will soon be available as a pill after years as an ...

Lipfendra (enlicitide) offers a convenient option for adults who haven’t been able to lower their cholesterol sufficiently with statins. The U.S. Food and Drug Administration (FDA) approved Lipfendra ...

Merck’s pill, called Lipfendra, is a PCSK9 inhibitor, which works in a different way from a statin to lower cholesterol.

The FDA approved enlicitide (Lipfendra) as the first oral PCSK9 inhibitor for lowering cholesterol. Enlicitide is now ...

Key Points Interested in Agenus Inc.? Here are five stocks we like better. Agenus is prioritizing its Phase 3 ROBBIN trial of ...

(Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross ...